Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer

Ashworth, 2013, Is there an oligometastatic state in non-small cell lung cancer? a systematic review of the literature., Lung Cancer, 82, 197, 10.1016/j.lungcan.2013.07.026

Weichselbaum, 2011, Oligometastases revisited., Nat Rev Clin Oncol, 8, 378, 10.1038/nrclinonc.2011.44

Ashworth, 2014, An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non–small-cell lung cancer., Clin Lung Cancer, 15, 346, 10.1016/j.cllc.2014.04.003

Griffioen, 2013, Radical treatment of synchronous oligometastatic non–small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors., Lung Cancer, 82, 95, 10.1016/j.lungcan.2013.07.023

Gomez, 2016, Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study., Lancet Oncol, 17, 1672, 10.1016/S1470-2045(16)30532-0

Gomez, 2019, Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study., J Clin Oncol, JCO1900201

Iyengar, 2018, Consolidative radiotherapy for limited metastatic non–small-cell lung cancer: a phase 2 randomized clinical trial., JAMA Oncol, 4, e173501, 10.1001/jamaoncol.2017.3501

Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer., J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375

Socinski, 2013, Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer., Ann Oncol, 24, 2390, 10.1093/annonc/mdt235

Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer., N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774

Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer., N Engl J Med, 378, 2078, 10.1056/NEJMoa1801005

Paz-Ares, 2018, Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer., N Engl J Med, 379, 2040, 10.1056/NEJMoa1810865

Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC., N Engl J Med, 379, 2342, 10.1056/NEJMoa1809697

Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer., N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937

Pignon, 2008, Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group., J Clin Oncol, 26, 3552, 10.1200/JCO.2007.13.9030

Pennell, 2019, SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non–small-cell lung cancer., J Clin Oncol, 37, 97, 10.1200/JCO.18.00131

Donnem, 2015, Stromal CD8+ T-cell density: a promising supplement to TNM staging in non–small cell lung cancer., Clin Cancer Res, 21, 2635, 10.1158/1078-0432.CCR-14-1905

Cella, 1995, Reliability and validity of the Functional Assessment of Cancer Therapy–Lung (FACT-L) quality of life instrument., Lung Cancer, 12, 199, 10.1016/0169-5002(95)00450-F

Heinze, 2001, A solution to the problem of monotone likelihood in Cox regression., Biometrics, 57, 114, 10.1111/biom.2001.57.issue-1

Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1–positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial., Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7

Mok, 2019, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial., Lancet, 393, 1819, 10.1016/S0140-6736(18)32409-7

Lussier, 2012, Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs., PLoS One, 7, e50141, 10.1371/journal.pone.0050141

Wuttig, 2009, Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient., Int J Cancer, 125, 474, 10.1002/ijc.v125:2

Mujoo, 2018, Harnessing and optimizing the interplay between immunotherapy and radiotherapy to improve survival outcomes., Mol Cancer Res, 16, 1209, 10.1158/1541-7786.MCR-17-0743

Rodriguez-Ruiz, 2016, Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming., Cancer Res, 76, 5994, 10.1158/0008-5472.CAN-16-0549

Luke, 2018, Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors., J Clin Oncol, 36, 1611, 10.1200/JCO.2017.76.2229